Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.32)
# 4,160
Out of 4,893 analysts
38
Total ratings
15.62%
Success rate
-25.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Overweight | $55 | $39.71 | +38.50% | 3 | May 14, 2025 | |
| VERV Verve Therapeutics | Upgrades: Overweight | n/a | $11.06 | - | 4 | Apr 15, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $22.03 | - | 12 | Mar 12, 2025 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $68.86 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $12.16 | +434.54% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $1.74 | - | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $3.06 | +357.52% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $59.00 | +81.36% | 4 | Aug 8, 2022 |
Legend Biotech
May 14, 2025
Reiterates: Overweight
Price Target: $55
Current: $39.71
Upside: +38.50%
Verve Therapeutics
Apr 15, 2025
Upgrades: Overweight
Price Target: n/a
Current: $11.06
Upside: -
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.03
Upside: -
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $68.86
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $12.16
Upside: +434.54%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.74
Upside: -
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $3.06
Upside: +357.52%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $59.00
Upside: +81.36%